Journal article
A novel ex vivo immunoproteomic approach characterising Fasciola hepatica tegumental antigens identified using immune antibody from resistant sheep
TC Cameron, I Cooke, P Faou, H Toet, D Piedrafita, N Young, V Rathinasamy, T Beddoe, G Anderson, R Dempster, TW Spithill
International Journal for Parasitology | ELSEVIER SCI LTD | Published : 2017
Abstract
A more thorough understanding of the immunological interactions between Fasciola spp. and their hosts is required if we are to develop new immunotherapies to control fasciolosis. Deeper knowledge of the antigens that are the target of the acquired immune responses of definitive hosts against both Fasciola hepatica and Fasciola gigantica will potentially identify candidate vaccine antigens. Indonesian Thin Tail sheep express a high level of acquired immunity to infection by F. gigantica within 4 weeks of infection and antibodies in Indonesian Thin Tail sera can promote antibody-dependent cell-mediated cytotoxicity against the surface tegument of juvenile F. gigantica in vitro. Given the high ..
View full abstractGrants
Funding Acknowledgements
This work in the T.W.S. laboratory was supported by funds from Linkage Project LP130100943 "Development of a novel vaccine targeting parasite tegument proteins for liver fluke disease in livestock" and Linkage Project LP160100442 "Optimisation of a novel hybrid vaccine for liver fluke disease in cattle" funded by the Australian Research Council, in collaboration with Virbac (Australia) Pty. Ltd., as well as support from La Trobe University, Melbourne, Australia. T.C. has been supported by a PhD scholarship from La Trobe University and a La Trobe University School of Life Sciences Postgraduate Publication Award. V.R. was supported by a Victorian-India Doctoral Scholarship from the Australia India Institute, a PhD scholarship from La Trobe University and a La Trobe University School of Life Sciences Postgraduate Publication Award. T.B. was supported by Pfizer Australia Research Fellowship. Funding from the National Health Medical Research Council (NHMRC) of Australia is gratefully acknowledged (N.D.Y.).